

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version
5.1

Revision Date:
14.04.2025

SDS Number:
441469-00022

Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ceftolozane / Tazobactam Injection Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Respiratory sensitisation : Category 1

Specific target organ toxicity - : Category 2 (Kidney, Liver)
repeated exposure

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

GHS label elements

Hazard pictograms :



Signal word : Danger

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version
5.1

Revision Date:
14.04.2025

SDS Number:
441469-00022

Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Hazard statements	: H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. H373 May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure. H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements	: Prevention: P233 Keep container tightly closed. P260 Do not breathe dust. P271 Use only outdoors or with adequate ventilation. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing. P284 Wear respiratory protection. Response: P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P319 Get medical help if you feel unwell. P342 + P316 If experiencing respiratory symptoms: Get emergency medical help immediately. P391 Collect spillage. Storage: P403 Store in a well-ventilated place. Disposal: P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Ceftolozane	689293-68-3	>= 30 - < 50
Tazobactam	89786-04-9	>= 10 - < 20
Sodium chloride	7647-14-5	>= 10 - < 20

4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air.

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version 5.1	Revision Date: 14.04.2025	SDS Number: 441469-00022	Date of last issue: 28.09.2024 Date of first issue: 06.01.2016
----------------	------------------------------	-----------------------------	---

In case of skin contact	If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention. : In case of contact, immediately flush skin with soap and plenty of water.
In case of eye contact	Get medical attention if symptoms occur. : If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water. : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome). Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause damage to organs through prolonged or repeated exposure.
Most important symptoms and effects, both acute and delayed	Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Protection of first-aiders	Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Metal oxides Chlorine compounds Nitrogen oxides (NO _x)
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version
5.1

Revision Date:
14.04.2025

SDS Number:
441469-00022

Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.

Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

Keep container tightly closed.

Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease,

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version 5.1	Revision Date: 14.04.2025	SDS Number: 441469-00022	Date of last issue: 28.09.2024 Date of first issue: 06.01.2016
----------------	------------------------------	-----------------------------	---

Conditions for safe storage	: Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Ceftolozane	689293-68-3	TWA	1000 µg/m ³ (OEB 1)	Internal
		Further information: DSEN, RSEN		
Tazobactam	89786-04-9	Wipe limit	100 µg/100 cm ²	Internal
		Further information: RSEN		
		Wipe limit	250 µg/m ³ (OEB 2)	Internal
			100 µg/100 cm ²	Internal

Engineering measures : Use feasible engineering controls to minimize exposure to compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version
5.1

Revision Date:
14.04.2025

SDS Number:
441469-00022

Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version 5.1 Revision Date: 14.04.2025 SDS Number: 441469-00022 Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Water solubility	: No data available
Partition coefficient: n-octanol/water	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics	
Particle size	: No data available

10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	: Inhalation Skin contact Ingestion Eye contact
--	--

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	: Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
---------------------	--

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version 5.1 Revision Date: 14.04.2025 SDS Number: 441469-00022 Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Components:

Ceftolozane:

Acute toxicity (other routes of administration) : LD50 (Rat): > 2,000 mg/kg
Application Route: Intravenous

LD50 (Mouse): > 1,500 mg/kg
Application Route: Intravenous

LD50 (Dog): > 2,000 mg/kg
Application Route: Intravenous

Tazobactam:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 5,000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): > 5,000 mg/kg
Application Route: Intravenous

LD50 (Mouse): > 5,000 mg/kg
Application Route: Intravenous

LD50 (Dog): > 5,000 mg/kg
Application Route: Intravenous

Sodium chloride:

Acute oral toxicity : LD50 (Rat): 3,550 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 42 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Sodium chloride:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Sodium chloride:

Species : Rabbit

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version 5.1 Revision Date: 14.04.2025 SDS Number: 441469-00022 Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Ceftolozane:

Test Type : Maximisation Test
Species : Guinea pig
Result : Sensitiser

Tazobactam:

Result : Sensitiser

Sodium chloride:

Test Type : Local lymph node assay (LLNA)
Exposure routes : Skin contact
Species : Mouse
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Ceftolozane:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: positive

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version
5.1

Revision Date:
14.04.2025

SDS Number:
441469-00022

Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Species: Mouse
Result: negative

Tazobactam:

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: positive

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster fibroblasts
Result: negative

Genotoxicity in vivo

: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo
Species: Mouse
Result: negative

Sodium chloride:

Genotoxicity in vitro

: Test Type: In vitro mammalian cell gene mutation test
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Saccharomyces cerevisiae, gene mutation assay (in vitro)
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: positive

Test Type: Chromosome aberration test in vitro
Result: positive

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo

: Test Type: In vivo micronucleus test
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version
5.1

Revision Date:
14.04.2025

SDS Number:
441469-00022

Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Intraperitoneal injection
Result: positive

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

Sodium chloride:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Ceftolozane:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Intravenous injection
Fertility: NOAEL: 1,000 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Mouse
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 2,000 mg/kg body weight
Remarks: No significant adverse effects were reported

Test Type: Embryo-foetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Remarks: No significant adverse effects were reported

Tazobactam:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Intraperitoneal injection
Fertility: NOAEL: 640 mg/kg body weight

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version
5.1

Revision Date:
14.04.2025

SDS Number:
441469-00022

Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Effects on foetal development

: Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal injection
Developmental Toxicity: NOAEL: 40 mg/kg body weight
Result: Effects on early embryonic development

Test Type: Embryo-foetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 3,000 mg/kg body weight
Result: No effects on foetal development

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Components:

Ceftolozane:

Target Organs : Kidney
Assessment : May cause damage to organs through prolonged or repeated exposure.

Tazobactam:

Target Organs : Liver
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Ceftolozane:

Species : Rat
NOAEL : 1,000 mg/kg
Application Route : Intravenous
Exposure time : 28 days
Target Organs : Kidney
Symptoms : No adverse effects

Species : Dog
LOAEL : 300 mg/kg
Exposure time : 28 days
Target Organs : Kidney

Tazobactam:

Species : Rat
NOAEL : 40 mg/kg
Application Route : Intraperitoneal

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version 5.1 Revision Date: 14.04.2025 SDS Number: 441469-00022 Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Exposure time : 6 Months
Target Organs : Liver

Species : Dog
NOAEL : 40 mg/kg
LOAEL : 80 mg/kg
Application Route : Intraperitoneal
Exposure time : 6 Months
Target Organs : Liver

Sodium chloride:

Species : Rat
LOAEL : 2,533 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ceftolozane:

Ingestion : Symptoms: Diarrhoea, Fever, Headache, Nausea, Skin irritation, Gastrointestinal discomfort

Tazobactam:

Inhalation : Remarks: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ceftolozane:

Toxicity to algae/aquatic plants : EC50 (Anabaena flos-aquae): 0.0401 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 0.0018 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version 5.1 Revision Date: 14.04.2025 SDS Number: 441469-00022 Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Method: OECD Test Guideline 209

NOEC: 560 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 10 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 9.6 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 10

Tazobactam:

Toxicity to algae/aquatic plants : EC50 (Anabaena flos-aquae): 0.96 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 0.44 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 1

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 10.6 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 9.6 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version 5.1 Revision Date: 14.04.2025 SDS Number: 441469-00022 Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

Sodium chloride:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 5,840 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 4,136 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50: > 2,000 mg/l
Exposure time: 96 h

Toxicity to microorganisms : EC10: > 1,000 mg/l

Toxicity to fish (Chronic toxicity) : NOEC: 252 mg/l
Exposure time: 33 d
Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 314 mg/l
Exposure time: 21 d
Species: Daphnia pulex (Water flea)

Persistence and degradability

Components:

Ceftolozane:

Biodegradability : Result: Not readily biodegradable.
Method: OECD Test Guideline 301D

Tazobactam:

Biodegradability : Result: Not readily biodegradable.
Method: OECD Test Guideline 301D

Bioaccumulative potential

Components:

Ceftolozane:

Partition coefficient: n-octanol/water : log Pow: -0.21

Tazobactam:

Partition coefficient: n-octanol/water : log Pow: -0.63

Mobility in soil

Components:

Ceftolozane:

Distribution among environ- : log Koc: 3.3

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version 5.1 Revision Date: 14.04.2025 SDS Number: 441469-00022 Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

mental compartments Method: OECD Test Guideline 106

Tazobactam:

Distribution among environmental compartments : log Koc: 0.87

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Ceftolozane, Tazobactam)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Ceftolozane, Tazobactam)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Ceftolozane, Tazobactam)
Class : 9
Packing group : III

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.1	14.04.2025	441469-00022	Date of first issue: 06.01.2016

Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION

Revision Date	:	14.04.2025
---------------	---	------------

Further information

Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
---	---	---

Date format	:	dd.mm.yyyy
-------------	---	------------

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Con-

SAFETY DATA SHEET

according to the Globally Harmonized System



Ceftolozane / Tazobactam Injection Formula-tion

Version
5.1

Revision Date:
14.04.2025

SDS Number:
441469-00022

Date of last issue: 28.09.2024
Date of first issue: 06.01.2016

centration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN